IMbrave150: Atezolizumab plus Bevacizumab in HCC: Efficacy Data and Clinical Practice Implications : Episode 6
AE Management with Atezolizumab + Bevacizumab
Key opinion leaders examine IMbrave 150 data stratified by baseline varices and compare outcomes between patients with Child-Pugh A and B.
Video content above is prompted by the following:
- Please share your thoughts on the data based on baseline varices from IMbrave 150.
- Concerning safety data, is this in line with you what you see in practice for the vp4 and baseline varices?
- How do you currently manage AEs seen in practice?
- Please share your thoughts on the data based on Child-Pugh A vs B for IMbrave 150.
- How do you consider immunotherapy to be different for Child-Pugh A vs B?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
